title: [Development of an anti-CCR4 antibody, mogamulizumab, the first approved antibody made by POTELLIGENT(®) technology].
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Ishii
mesh_terms: D000818:Animals; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000920:Antibody-Dependent Cell Cytotoxicity / Q000276:immunology*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017277:Drug Approval; D055808:Drug Discovery / Q000379:methods*; D006801:Humans; D007564:Japan; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000188:drug therapy*; D051379:Mice; D058990:Molecular Targeted Therapy; D054398:Receptors, CCR4 / Q000276:immunology*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D054398:Receptors, CCR4; C549035:mogamulizumab